Document Detail

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.
MedLine Citation:
PMID:  21465314     Owner:  NLM     Status:  Publisher    
PURPOSE: Spisulosine is a marine compound that showed antitumor activity in preclinical studies. We report results of a phase I trial performed in patients with advanced solid tumors with the marine compound, with the aim to determine the maximum tolerated dose (MTD) of a weekly 3-h intravenous (iv.) infusion, and to evaluate the safety, efficacy, and pharmacokinetics (PK) of the compound. PATIENTS AND METHODS: Two centers contributed 25 patients to the trial, and 7 dose levels were explored. RESULTS: In dose levels ranging from 4 to 128 mg/m²/day, no dose-limiting toxicities (DLT) were observed. One patient had DLT at 200 mg/m², a reversible grade 3 ALT increase. The MTD was not reached due to early termination of the Spisulosine trial program but is considered to be likely in the range of 200 mg/m² for this schedule. Drug-related adverse reactions included mild to moderate nausea, pyrexia, injection site reactions, and vomiting. One case of grade 4 peripheral motor and sensory neuropathy associated with general weakness and pain was observed during treatment cycle 4 and possibly contributed to the death of the patient. Grade 3 laboratory abnormalities included anemia and lymphopenia and increases in liver enzymes (alkaline phosphatase, transaminases, and bilirubin). Objective responses were not observed, and only four patients had short-lasting stable disease (<3 months). The PK data indicated a wide distribution, a long residence time, and dose proportionality of the agent. CONCLUSIONS: Hepato- and neuro-toxicity are schedule independent dose-limiting adverse events for this marine compound, as illustrated by this and other early clinical trials.
P Schöffski; H Dumez; R Ruijter; B Miguel-Lillo; A Soto-Matos; V Alfaro; G Giaccone
Related Documents :
22119714 - Therapeutic dosing of fingolimod (fty720) prevents cell infiltration, rapidly suppresse...
10953714 - Cardiorespiratory responses and plasma cortisol concentrations in dogs treated with med...
10479354 - Pharmacokinetics of fluphenazine, a highly lipophilic drug, estimated from a pulse dose...
22183714 - Effects of alpinumisoflavone and abyssinone v-4'-methyl ether derived from erythrina ly...
3912084 - Effects of dopamine on renal function in the rat isolated perfused kidney.
15781064 - Effects of alpha1- and alpha2-adrenoreceptor antagonists on cold allodynia in a rat tai...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-5
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  -     ISSN:  1432-0843     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-4-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Herestraat 49, 3000, Leuven, Belgium,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide t...
Next Document:  Evaluation of functional ability of rheumatoid arthritis based on HAQ score and BMD among South Indi...